Pantel, K. & Alix-Panabières, C. Liquid biopsy and minimal residual disease—Latest advances and implications for cure. Nat. Rev. Clin. Oncol. 16(7), 409–424. doi.org/10.1038/s41571-019-0187-3 (2019).
Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nat. Rev. Cancer 4, 448–456 (2004).
Scher, H. I. et al. Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer. Can. Res. 77, 5687–5698 (2017).
Manjunath, Y. et al. PD-L1 expression with epithelial mesenchymal transition of circulating tumor cells is associated with poor survival in curatively resected non-small cell lung cancer. Cancers 11, 806 (2019).
Mittal, V. Epithelial mesenchymal transition in tumor metastasis. Annu. Rev. Pathol. 13, 395–412 (2018).
Williamson, S. C. et al. Vasculogenic mimicry in small cell lung cancer. Nat. Commun. 7, 1–14 (2016).
Lin, P. P. Aneuploid circulating tumor-derived endothelial cell (CTEC): A novel versatile player in tumor neovascularization and cancer metastasis. Cells 9, 1539 (2020).
Dao, L. et al. Prognostic value of cell-surface vimentin-positive CTCs in pediatric sarcomas. Front. Oncol. 11, 760267. doi.org/10.3389/fonc.2021.760267 (2021).
Pantel, K. & Alix-Panabières, C. Circulating tumour cells in cancer patients: Challenges and perspectives. Trends Mol. Med. 16, 398–406 (2010).
Bailey, P. C. & Martin, S. S. Insights on CTC biology and clinical impact emerging from advances in capture technology. Cells. 8(6), 553. doi.org/10.3390/cells8060553 (2019).
Hou, S. et al. Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew. Chem. 125, 3463–3467 (2013).
Aya-Bonilla, C. et al. Immunomagnetic-enriched subpopulations of melanoma circulating tumour cells (CTCs) exhibit distinct transcriptome profiles. Cancers 11, 157 (2019).
Rapanotti, M. C. et al. Stem-mesenchymal signature cell genes detected in heterogeneous circulating melanoma cells correlate with disease stage in melanoma patients. Front. Mol. Biosci. 7, 92 (2020).
Guadagni, S. et al. A pilot study of the predictive potential of chemosensitivity and gene expression assays using circulating tumour cells from patients with recurrent ovarian cancer. Int. J. Mol. Sci. 21, 4813 (2020).
Ferrarini, A. et al. A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. PLoS ONE 13, e0193689 (2018).
Beasley, A. et al. Clinical application of circulating tumor cells and circulating tumor DNA in uveal melanoma. JCO Precis. Oncol. 2, 1–12 (2018).
Asante, D.-B., Calapre, L., Ziman, M., Meniawy, T. M. & Gray, E. S. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. Cancer Lett. 468, 59–71 (2020).
Asante, D.-B. et al. Multi-marker immunofluorescent staining and PD-L1 detection on circulating tumour cells from ovarian cancer patients. Cancers 13, 6225 (2021).
Kamal, M. et al. Cytopathologic identification of circulating tumor cells (CTCs) in breast cancer: Application of size-based enrichment. Clin. Diagn. Pathol. 4, 1–5 (2019).
Bitting, R. L. et al. Development of a method to isolate circulating tumor cells using mesenchymal-based capture. Methods 64, 129–136 (2013).
Cheng, H. et al. Combined detection and subclass characteristics analysis of CTCs and CTECs by SE-iFISH in ovarian cancer. Chin. J. Cancer Res. 33, 256 (2021).
Zhang, L. et al. PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients. Cancer Lett. 469, 355–366 (2020).
Network, C. G. A. R. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609 (2011).
Kuo, K.-T. et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Can. Res. 69, 4036–4042 (2009).
Salmon, C. et al. Image-based identification and genomic analysis of single circulating tumor cells in high grade serous ovarian cancer patients. Cancers 13, 3748 (2021).
Riethdorf, S., O’Flaherty, L., Hille, C. & Pantel, K. Clinical applications of the Cell Search platform in cancer patients. Adv. Drug Deliv. Rev. 125, 102–121 (2018).
Schwarz, R. F. et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: A phylogenetic analysis. PLoS Med. 12, e1001789 (2015).
Lanuti, P. et al. A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. Sci. Rep. 8, 1–10 (2018).
Liu, Z. et al. CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer: Analysis on ALTER-0303 study. Cancer Med. 7, 3011–3021 (2018).
Starlinger, P. et al. Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. Neoplasia 13, 980–990 (2011).
Nagl, L., Horvath, L., Pircher, A. & Wolf, D. Tumor endothelial cells (TECs) as potential immune directors of the tumor microenvironment–new findings and future perspectives. Front. Cell Dev. Biol. 8, 766 (2020).
Bidard, F.-C. et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann. Oncol. 21, 1765–1771 (2010).
Rahbari, N. N. et al. Prognostic value of circulating endothelial cells in metastatic colorectal cancer. Oncotarget 8, 37491 (2017).
Po, J. W. et al. Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. J.Circul. Biomark. 7, 1849454418782617 (2018).
Haunschild, C. E. & Tewari, K. S. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 16, 225–246 (2020).
Pirtea, L., Raica, M. & Cimpean, A. M. Endothelial cell activation and proliferation in ovarian tumors: Two distinct steps as potential markers for antiangiogenic therapy response. Mol. Med. Rep. 5, 1181–1184 (2012).
Pantel, K. et al. Circulating epithelial cells in patients with benign colon diseases. Clin. Chem. 58, 936–940 (2012).
Jou, H.-J. et al. An automatic platform based on nanostructured microfluidic chip for isolating and identification of circulating tumor cells. Micromachines 12, 473 (2021).
Guo, Y.-X. et al. Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer. Oncotarget 9, 7522 (2018).
Nair, N. et al. Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer: A prospective cross-sectional study. PLoS Med. 13, e1002206 (2016).
Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8, 1–13 (2017).
Read more here: Source link